Recently, the modified anti-ERC/mesothelin therapies have been developed to enhance its anti-tumor activities [11,17], and these new agents include antibodies linked to Pseudomonas exotoxin [18], or those conjugated with a tubulin inhibitor [19], or anti-ERC/mesothelin CAR-T cells [20,21,22]. The gene discussed is MSLN; the disease is neoplasm.